Aromatase inhibitor used to treat ER-positive breast cancer. It suppresses estrogen synthesis and induces apoptosis in breast cancer cells, Each
$ 295.10
|
|
Details:
Anastrozole is a third generation aromatase inhibitor that suppresses synthesis of estrogen. Anastrozole exhibits anticancer chemotherapeutic activity and is clinically used to treat ER-positive breast cancer. In vitro, anastrozole inhibits proliferation of cancer cells by disrupting the mitochondrial membrane potential and inducing apoptosis. Because of its anti-estrogen properties, anastrozole may decrease bone mineral density and increase fracture risk.
Additional Information
| SKU | 5584140 |
|---|---|
| UOM | Each |
| UNSPSC | 12352200 |
| Manufacturer Part Number | A5302-100 mg |
| CAS Number | 120511-73-1 |
| HS Code | 2933998000 |
|---|---|
| UN Number | UN 3249 |
| Proper Shipping Name | Anastrozole |
| Packaging Group | PG III |
| Hazardous Class | 6.1 (b) |
| Label | ![]() |
| Molecular Formula | C17H19N5 |
| EC Number | 601-715-6 |
| Hazard Statement | H302-H360FD |
| Precautionary Statements | P201-P301+P312+P330-P308+P313-P280 |
| Risk Statements | 36/37/38-22-61-60 |
| GHS | GHS07,GHS08 |
| GHS (Pictogram) | ![]() ![]() |
| Safety Statements | 26-37/39 |
| Hazard Code | Xi,X |
| Signal Word | Danger |
.jpg)


